Two-Stage Adaptive Designs for Three-Treatment Bioequivalence Studies.
Grayling, Michael J
Mander, Adrian P
Wason, James MS
Stat Biopharm Res
Informa UK Limited
MetadataShow full item record
Grayling, M. J., Mander, A. P., & Wason, J. M. (2019). Two-Stage Adaptive Designs for Three-Treatment Bioequivalence Studies.. Stat Biopharm Res, 11 (4), 360-374. https://doi.org/10.1080/19466315.2019.1654911
Bioequivalence (BE) studies are most often conducted as crossover trials, and therefore establishing their required sample size necessitates specification of the within-person variance. Given that this specification is often difficult in practice, there has been great interest in recent years in the use of adaptive designs for BE trials. However, while numerous methods for this have now been presented, their focus has been solely on two-treatment BE studies. In some instances, it will be desired to incorporate more than a single test and reference formulation into a BE trial. It would therefore be useful to establish methodology for the design of adaptive multi-treatment BE trials, to acquire the benefits in the two-treatment setting in this more complex situation. Here, we achieve this for three-treatment studies by extending previously proposed designs for two-treatment trials. First, we discuss the additional design considerations that arise when multiple comparisons are made. Next, an extensive simulation study is employed to compare the performance of the proposed procedures. With this, we demonstrate that two-stage designs with desirable statistical operating characteristics can be readily identified for three-treatment BE trials. Supplementary materials for this article are available online.
Interim analysis, Re-estimation, Sequential, Unblinded
Wellcome Trust (099770/Z/12/Z)
External DOI: https://doi.org/10.1080/19466315.2019.1654911
This record's URL: https://www.repository.cam.ac.uk/handle/1810/338407
Attribution-NonCommercial 4.0 International
Licence URL: https://creativecommons.org/licenses/by-nc/4.0/